Therapeutic agent for disease based on inhibitory effect of macrophage migration inhibitory factor

Abstract

A benzopyran derivative represented by general formula [1], or a salt thereof, is useful in therapeutic or preventive treatment of disease, wherein said therapeutic or preventive treatment is effective because said benzopyran derivative, or salt thereof, binds to MIF, has an MIF inhibitory effect, and inhibits MIF. [In the formula, R 1 represents an optionally substituted C 1-6 alkyl group, one of R 2 and R 3 represents a hydrogen atom, and the other of R 2 and R 3 represents a hydrogen atom, an optionally substituted amino group, an optionally substituted acylamino group, an optionally substituted carbamoyl group, or an optionally substituted aryl group.]

1 - 8 . (canceled) 
     
     
         9 . A treatment agent for the relapsing-remitting or secondary progressive multiple sclerosis at the time of relapse, comprising a benzopyran derivative represented by the following general formula or a salt thereof, 
       
         
           
           
               
               
           
         
         wherein R 1  represents an optionally substituted C 1-6  alkyl group; one of R 2  and R 3  represents a hydrogen atom; and the other of R 2  and R 3  represents a hydrogen atom, an optionally substituted amino group, an optionally substituted acylamino group, an optionally substituted carbamoyl group or an optionally substituted aryl group. 
       
     
     
         10 . The treatment agent for the relapsing-remitting or secondary progressive multiple sclerosis at the time of relapse according to  claim 9 , wherein one of R 2  and R 3  represents a hydrogen atom; and the other of R 2  and R 3  represents an optionally substituted acylamino group. 
     
     
         11 . The treatment agent for the relapsing-remitting or secondary progressive multiple sclerosis at the time of relapse according to  claim 9 , wherein the benzopyran derivative is N-[7-(methylsulfonyl)amino]-4-oxo-6-phenoxy-4H-1-benzopyran-3-yl]formamide, N-(3-amino-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl)methanesulfonamide, N-[7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4H-1-benzopyran-3-yl]acetamide, N-(4-oxo-6-phenoxy-4H-1-benzopyran-7-yl)methanesulfonamide, 7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4H-1-benzopyran-2-carboxamide, N-[7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4H-1-benzopyran-2-yl]acetamide, 7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4H-1-benzopyran-3-carboxamide, N-[7-[(ethylsulfonyl)amino]-4-oxo-6-phenoxy-4H-1-benzopyran-3-yl]formamide or N-(4-oxo-6-phenoxy-2-phenyl-4H-1-benzopyran-7-yl)methanesulfonamide. 
     
     
         12 . The treatment agent for the relapsing-remitting or secondary progressive multiple sclerosis at the time of relapse according to  claim 9 , wherein the benzopyran derivative is N-[7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4H-1-benzopyran-3-yl]formamide.